Determination of Hyperforin in Mouse Brain by High-Performance Liquid Chromatography/Tandem Mass Spectrometry
- 9 October 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 75 (22), 6084-6088
- https://doi.org/10.1021/ac034520z
Abstract
Hyperforin is one of the essential active ingredients of St. John's wort extract, which is used as an antidepressant for mild to moderately severe depressions. In vitro and in vivo data as well as several clinical studies and meta analyses have confirmed the pharmacological effect of treatment with hyperforin-containing preparations. However, little is known about the brain availability of hyperforin until now. Accordingly, a highly sensitive and selective LC/MS method for this purpose was developed and validated. This method proved suitable for the determination of hyperforin in mouse brain, after oral administration of hyperforin sodium salt and St. John's wort extract. This method involves liquid−liquid extraction of hyperforin with ethyl acetate followed by separation with rapid reversed-phase high-performance liquid chromatography and tandem mass spectrometry detection using electrospray ionization. Excellent linearity was obtained for the entire calibration range from 0.25 to 10 ng/mL (corresponding to 2.5−100 ng/g brain tissue concentration, calculated with the factor derived from sample processing) with an average coefficient of correlation of 0.9992. The recovery of hyperforin from mouse brain homogenates was between 71.4 and 75.3% with a relative standard deviation of less than 3%. Validation assays for the lower limit of quantitation yielded an accuracy of 5.8%. Intraday accuracy and precision for the developed method were between 4.6 and 10.6% and 4.3−8.4%, respectively, while the interday parameters varied between 6.7 and 12.2% for accuracy and 2.0−5.0% for precision. After the method validation, hyperforin brain levels in mice, treated with 15 mg/kg hyperforin (either as the sodium salt or as 5% St. John's wort extract), were investigated. The average concentration of hyperforin found for the sodium salt group was 28.8±10.1 ng/g of brain (n = 8), which was somewhat higher than the hyperforin concentration of 15.8±10.9 ng/g of brain (n = 8), determined in the extract-treated group. This method is robust, selective, and highly sensitive and represents an appropriate tool to further prove the occurrence and distribution of hyperforin in mouse brain.Keywords
This publication has 23 references indexed in Scilit:
- Current St. John's wort research from mode of action to clinical efficacyPharmacological Research, 2003
- Efficacy of St. John’s Wort Extract WS 5570 in Major Depression: A Double-Blind, Placebo-Controlled TrialAmerican Journal of Psychiatry, 2002
- A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical reviewInternational Clinical Psychopharmacology, 2001
- Hypericum perforatum - a Review of Clinical StudiesPharmacopsychiatry, 2001
- Effectiveness of St John's Wort in Major DepressionJAMA, 2001
- St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literaturePsychopharmacology, 2001
- St John's Wort for DepressionArchives of Internal Medicine, 2000
- Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks Commentary: Has hypericum found its place in antidepressant treatment?BMJ, 1999
- The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)Molecular Psychiatry, 1999
- Solubilized Hypericin and Pseudohypericin fromHypericum perforatumExert Antidepressant Activity in the Forced Swimming Test3Planta Medica, 1998